|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Arkansas |
|---|---|
| Collaborator: |
National Institute on Drug Abuse (NIDA) |
| Information provided by: | University of Arkansas |
| ClinicalTrials.gov Identifier: | NCT00733239 |
Purpose
This study involves giving psychoactive drugs intramuscularly (injected into the muscle of the upper arm or the hip) and/or orally, and measuring the subject's ability to tell the difference between one drug and another, as well as measuring the effects of the drugs on mood, physiology (e.g., heart rate, blood pressure, respiration rate) and behavior. Each subject will receive 2-4 of the listed interventions.
| Condition | Intervention | Phase |
|---|---|---|
|
Opiate Dependence |
Drug: 2-4 of the drugs listed below |
Phase I |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Basic Science |
| Official Title: | Drug Discrimination in Methadone-Maintained Humans Study 2 |
| Estimated Enrollment: | 40 |
| Study Start Date: | August 2008 |
| Estimated Study Completion Date: | September 2010 |
| Estimated Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
Receives 2-4 of the drugs listed under Intervention
|
Drug: 2-4 of the drugs listed below
Cycloserine: 500, 675, 750 mg oral capsule may possibly be given Diltiazem: 30, 60, 120 mg oral capsule may possibly be given Gabapentin: 100, 200, 400 mg oral capsule may possibly be given Isradipine: 5, 10 mg oral capsule may possibly be given Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given Nifedipine: 5, 10, 20 mg oral capsule may possibly be given Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given Saline: I.M. injection may possibly be given Verapamil: 30, 60, 120 mg oral capsule may possibly be given
Other Names:
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Arkansas | |
| University of Arkansas for Medical Sciences | |
| Little Rock, Arkansas, United States, 72205 | |
| Principal Investigator: | Alison Oliveto, Ph.D. | University of Arkansas |
More Information
| Responsible Party: | Alison Oliveto, Ph.D./Principal Investigator, University of Arkansas for Medical Sciences |
| ClinicalTrials.gov Identifier: | NCT00733239 History of Changes |
| Other Study ID Numbers: | R01-DA010017-02, R01DA010017-02, 104881, 5 R01 DA010017-02, DPMCDA |
| Study First Received: | August 11, 2008 |
| Last Updated: | February 2, 2011 |
| Health Authority: | United States: Food and Drug Administration |
|
methadone opioid dependence opioid |
|
Opioid-Related Disorders Substance-Related Disorders Mental Disorders Diltiazem Verapamil Nifedipine Gabapentin Isradipine Cycloserine Methadone Naloxone Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Pharmacologic Actions |
Cardiovascular Agents Therapeutic Uses Antihypertensive Agents Vasodilator Agents Anti-Arrhythmia Agents Anti-Infective Agents, Urinary Anti-Infective Agents Renal Agents Antibiotics, Antitubercular Anti-Bacterial Agents Antitubercular Agents Antimetabolites Analgesics, Opioid Analgesics Sensory System Agents |